Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE-C lumasiran study in advanced primary hyperoxaluria type 1
NL-OMON49207Phase 3Active, not recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1) (2 cohorts), sponsored by Alnylam Pharmaceuticals. Primary endpoints: Percent change in plasma oxalate from Baseline to Month 6 and Percent change in pre-dialysis plasma oxalate from Baseline to Month 6. Started Jul 2020; status: active, not recruiting.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NL-OMON49207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49207.